Aytu BioPharma Q1 revenue beats estimates on higher EXXUA sales
AYTU•Aytu BioPharma’s fiscal Q1 revenue rose 6.9% to $14.84 million, above the $13.27 million analyst estimate, while its adjusted EBITDA loss narrowed to $2.60 million. The company is to be acquired by Rosemont Pharmaceuticals for $2.70 per share in cash.
1. Revenue and loss
Aytu BioPharma said fiscal Q1 revenue increased 6.9% to $14.84 million, beating analyst expectations of $13.27 million. Adjusted EBITDA loss was $2.60 million, narrower than the $2.93 million estimate, and net loss was $3.88 million.
2. Portfolio trends
The company attributed revenue growth to higher EXXUA sales and a 33% sequential increase in prescriptions. ADHD portfolio revenue fell as the company reduced promotional emphasis and faced generic competition, while pediatric portfolio revenue increased on improved payer mix and lower returns. Aytu BioPharma did not provide specific guidance for future quarters or the full year.
3. Pending acquisition
Rosemont Pharmaceuticals has agreed to acquire Aytu BioPharma for $2.70 per share in cash.




